Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial

Authors: Aaron M. Gusdon, Nauder Faraday, John S. Aita, Sunil Kumar, Ishan Mehta, HuiMahn A. Choi, Jeffery L. Cleland, Keith Robinson, Louise D. McCullough, Derek K. Ng, Rangaramanujam M. Kannan, Sujatha Kannan

Published: 2022-07-20

DOI: 10.1126/scitranslmed.abo2652

Source: Full article

---

Abstract

Hyperinflammation triggered by SARS-CoV-2 is a major cause of disease severity, with activated macrophages implicated in this response. OP-101, a hydroxyl-polyamidoamine dendrimer–